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Objectives: The definition of circulatory impairment in the premature infant is
controversial. Current research suggests overdiagnosis and overtreatment. We aimed to
analyse which biomarkers move clinicians to initiate cardiovascular treatment (CVT). The
prognostic capacity for adverse outcome (death and/or moderate-severe brain damage
by cranial ultrasound at term equivalent) of these biomarkers was evaluated.
Study Design: Retrospective data analysis from preterm infants enrolled in a
placebo-controlled trial on dobutamine for low superior vena cava (SVC) flow, who
showed normal SVC flow within the first 24 h (not randomized). Five positive biomarkers
were considered: MABP < gestational age (GA)-1 mmHg; MABP < GA-5 mmHg; lactate
> 4 mmol/L; BE < −9 mmol/L; SVC flow <51 ml/kg/min.
Results: Ninety eight infants formed the study cohort. Thirty six received CVT (2–95 h).
Logistic regression models adjusted for gestational age showed a positive association
between CVT and the risk of death or moderate-severe abnormal cranial ultrasound at
term equivalent [(OR 5.2, 95%CI: 1.8–15.1) p= 0.002]. MABP<GA-1mmHg and lactate
> 4 mmol/L were the most prevalent biomarkers at start of treatment. Low BE, high
serum lactate and low SVC flow at first echocardiography showed a trend toward being
associated with adverse outcome, although not statistically significant.
Conclusions: Low blood pressure and high lactate are the most prevalent biomarkers
used for CVT prescription. Lactic acidosis and low SVC flow early after birth showed
a trend toward being associated with adverse outcome. These findings support using
a combination of biomarkers for inclusion in a placebo-controlled trial on CVT during
transitional circulation.
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INTRODUCTION
Circulatory impairment is a common complication of the
transitional circulation in the preterm infant (1). However, there
is no validated scoring system to guide the management of
this condition, leading to huge differences in approaches to
cardiovascular treatment (CVT) among clinicians (2–5). This is
a matter of the utmost importance, as several studies suggest the
use of such therapies may increase the risk of adverse outcome in
the most vulnerable population (6–8).
The literature increasingly supports the need of further work
on the assessment of efficacy and safety of CVT routinely used
in neonates; within the safeguards of high quality placebo-
controlled trials (9, 10). A key question in the design of
such trials is the entry criteria for randomization. Our work
addresses this question firstly by investigating which biomarkers
influence treatment decisions in routine clinical practice; and
secondly by evaluating their diagnostic-prognostic validity for
adverse outcome.
Hypotension is probably the most widely used biomarker
to initiate CVT (11, 12). However, the most common
pathophysiology underlying early circulatory failure during
transitional circulation in the preterm infant is characterized by
increased peripheral vascular resistance and increased afterload,
which may cause myocardial dysfunction and impaired blood
flow distribution, in spite of “normal” central blood pressure
(1, 13). An alternative to using low blood pressure alone to
initiate CVT is to focus on uneven blood flow distribution and
poor perfusion, using a combination of clinical and biochemical
parameters that indicate abnormalities of the macro- and
microcirculation. The parameters selected for investigation in
this work were mean arterial blood pressure (MABP), serum
lactate, base excess (BE) and superior vena cava (SVC) flow
measured by functional echocardiography; with the following
proposed biomarker cut-off values: MABP lower than the
gestational age minus 1 mmHg (MABP < GA-1 mmHg), MABP
lower than the gestational age minus 5 mmHg (MABP < GA-5
mmHg), SVC flow < 51 ml/kg/min, lactate > 4 mmol/L and BE
worse than−9 mmol/L (BE <−9).
Two cut-off values for MABP are being considered because
there is considerable variability amongst clinicians in the
threshold for intervention in the case of low blood pressure
(2, 8, 20): some clinicians following a less proactive approach of
permissive hypotension (6, 8), while others are not in “equipoise”
and treat hypotension right away to avoid the risk of cerebral
ischemia in case of impaired cerebral autoregulation. The first
cut-off value represents the “best practice” approach (MABP <
GA-1) which, although widely used clinically, does not constitute
a proven treatment threshold. The second cut-off value (MABP
< GA-5) was informed by two recent studies described next.
Firstly a large German cohort study (18) that included preterm
infants below 32 completed weeks, found that those whose
lowest MABP during the first 24 h from birth was in the lowest
quartile for gestational age (roughly, MABP < GA-5 mmHg)
Abbreviations: BE, base excess; CVT, cardiovascular treatment; GA, gestational
age; MABP, mean arterial blood pressure; SVC, superior vena cava.
had an increased risk for death, intraventricular hemorrhage
or bronchopulmonary dysplasia when compared with infants
with minimal MABP at or above the 25th percentile. Secondly
our group has recently reported a bivariate autoregressive
spectral coherence method to analyse the cerebral autoregulatory
capacity (19, 31). The method showed good sensitivity and
specificity for identifying infants with low SVC flow, theoretically
at risk of cerebral hypoperfusion, brain injury and impaired
neurodevelopment (32–35). In this study, infants with impaired
cerebral autoregulatory capacity were more prone to developing
severe intracranial hemorrhage and death. The autoregulation
classifier was associated with the percent of time of MABP
< GA-5 mmHg but not with MABP < GA-1mmHg, possibly
indicating the lowest range of the autoregulatory plateau. Thus
the second cut-off value (MABP < GA-5) is more congruent
with the pathophysiological pathway of the ischemia-reperfusion
injury in our previous studies (19, 31).
The SVC flow cut-off value is derived from an internal
(unpublished) reliability study for SVC flow measurement, to
address the theoretical variability of the method (36, 37). The
intra-observer repeatability index was 25% in our reliability
study. This index is defined as the repeatability coefficient
divided by the mean of all the measures (36) and indicates the
percentage of change between measurements that would have a
95% probability of not occurring due to chance or measurement
inaccuracy. To be sure that no infant is misdiagnosed, we
favor using the cut-off value of 51 ml/k/min that represents
the reported 41 ml/k/min cut-off value to define low SVC flow
according to previous studies (1, 32, 34, 35) plus 25%.
The proposed cut-off values of the laboratory early biomarkers
to be explored, lactate and BE, are supported by previous studies
(22, 23, 29, 30). In a similar population of newborns it has been
found that early hyperlactatemia (median highest lactate within
first 12 h from birth was 3.86 mmol/L) associated increased risk
for death (23). Both in ventilated infants (22) and in infants
diagnosed with necrotizing enterocolitis (29), higher lactate early
in the disease process carried increased adverse outcome.
The primary motivation of this study was to determine which
of the five chosen cut-off values would qualify as biomarkers
to be used as criterion for inclusion of patients in a future
phase III randomized clinical trial to demonstrate efficacy and
safety for dobutamine to treat hemodynamic insufficiency during
transitional circulation in the preterm infant (NEO-CIRC FP7;
HEALTH-2011.4.2-1) (14).
METHODS
A retrospective ad hoc analysis was conducted on data from a
pilot randomized placebo-controlled trial of dobutamine for low
superior vena cava flow (SVC flow) in preterm infants reported
elsewhere (14). From a total of 127 infants born <31 weeks
gestational age enrolled in the pilot trial there were 98 infants
classified as the “normal flow group” after showing SVC flow ≥
41 ml/kg/min in all scans performed during the first 24 h of life.
Unlike their “low flow group” complement these 98 infants were
not randomized to dobutamine or placebo and their condition
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was managed according to the criteria of the attending physician,
but without the use of dobutamine. Data from the normal flow
cohort was used to explore treatment decisions and outcomes
based on the five circulatory biomarker cut-off values described
in the introduction.
Prognostic capacity for combined adverse outcome of these
cut-off values was evaluated at two early study time points: the
immediate postnatal period of 2 h from birth, where no infant
was yet on CVT; and the baseline defined as the time of the first
echocardiography (Echo-D) scan within 12 h from birth, when
the majority of infants had not received any CVT.
For completeness, the remainder of this section presents a
brief description of assessments and intervention for both the
normal and low flow groups in the pilot trial, with full details
available from Bravo et al. (14).
After enrolment all infants had serial Echo-D scans at baseline,
60min after baseline (to re-assess normal flow) and at the
following times after birth: 12, 24, 48, 72, and 96 h. Heart
rate, peripheral oxygen saturation (SaO2), blood pressure (either
invasive or non-invasive), and urine output were recorded every
6 h during the first 96 h from birth. Biochemical parameters (pH,
blood gases, and serum lactate) were obtained when clinically
indicated. Infants with SVC flow < 41 ml/kg/min at any time
during the first 24 h of life (low flow group) were randomized
to receive dobutamine or placebo; whilst infants with SVC flow
≥ 41 ml/kg/min in all the scans performed during the first 24 h
of life (normal flow group) were not randomized but continued
in the trial for further assessment and follow-up and are the
subject of this report. The low flow group was excluded from this
retrospective analysis because it had a systematic and differential
intervention based on Echo-D findings that could eventually
influence their outcomes.
For all the infants (normal flow or low flow) open-label
treatment with other cardiovascular support that did not include
dobutamine was allowed if indicated by the attending physician
and was guided by a constellation of routine clinical or
biochemical data, following a standardized treatment protocol:
dopamine (first line), epinephrine (second line), plus/minus
volume expansion or hydrocortisone (15–17).
Main neonatal clinical outcomes were recorded at term
equivalent, together with combined adverse outcome
defined as: death; or moderate-severe abnormal cranial
ultrasound according to term equivalent ultrasound findings
(intraventricular hemorrhage grade 3; or periventricular
hemorrhagic infarct; or white matter damage, defined as
persistent periventricular echogenicity with/without associated
ventriculomegaly or cystic periventricular leukomalacia) (15, 17).
The study was approved by the hospital’s Ethics Committee.
Statistics
Quantitative (numerical) data are described as mean (SD),
median (IQR), and qualitative (categorical) data as counts
and percentages.
The Mann-Whitney rank-sum test and the Fisher’s exact
test were used for quantitative and qualitative data analysis,
respectively. The CVT effect and threshold biomarkers on
binary outcomes were assessed using Binary Logistics Regression
Analysis (unadjusted and adjusted for GA). The odds ratio and
the 95% confidence interval are reported. The CVT effect on
the quantitative outcome variables was assessed using an analysis
of covariance (ANCOVA) using the CVT as factor and GA age
as covariate. SAS 9.3 (SAS Institute, Cary, NC USA) was used
for analyses.
RESULTS
Patients
The median postnatal age at the first Echo-D (definition of
baseline) of the 98 patients in the normal flow group was 4 (3)
h. Among them, 36 infants were judged to suffer circulatory
impairment by the attending physician and received open-label
CVT (volume expansion or catecholamine or both, plus/minus
hydrocortisone) at a median postnatal age of 12.2 (5.4–23.2) h.
For those receiving only catecholamines (n = 17), the median
postnatal age at start on treatment was 12.5 (11–24) h. Infants
who received CVT were less mature, and had lower birth weight
and poorer condition at birth (Table 1). Outcomes at term
equivalent were also worse in these infants (Table 2) compared
to those who did not receive CVT. Logistic regression models
adjusted for gestational age showed that CVT (any type) andCVT
(only catecholamines) were associated with an increased risk of
combined adverse outcome (death or moderate-severe abnormal
cranial ultrasound according to term equivalent ultrasound
findings) [(OR 5.2, 95%CI: 1.8–15.1) p = 0.002] and [(OR 9.7,
95%CI: 2.6–36.5) p = 0.001], respectively. Severe ischemic event
(defined as spontaneous intestinal perforation or vascular spasm)
and posthemorrhagic hydrocephalus were observed in 2 and 3
infants, respectively, who received CVT. However, the logistic
regression analysis adjusted for gestational age could not be done
for them as no infants without CVT showed these outcomes.
Biomarkers and Cardiovascular Treatment
Prescription (Figure 1)
The extent to which having a positive biomarker (according to the
predefined cut-off values) influenced treatment decision is shown
in Table 3. High serum lactate > 4 mmol/L and hypotension
(MABP < GA-1) were the most prevalent biomarkers at the
time CVT was started. Having at least one positive biomarker
throughout the first 96 h of birth wasmore common among those
infants who received CVT (75%) than in the non-treated infants
(21%) (p < 0.01).
Biomarkers and Outcome at Term
Equivalent
High serum lactate levels at any time during the first 96 h from
birth were associated with an increased risk of death (p = 0.002)
and combined adverse outcome (p= 0.02). In addition, BE<−9
mmol/L was associated with increased risk of death (p= 0.01).
Table 4 shows results of the prognostic value for combined
adverse outcome of the explored biomarkers at both the
immediate postnatal and the baseline; with the combined adverse
outcome at term equivalent serving as the dependent variable
and the birth/baseline measurements for each biomarker serving
as independent variables. The following biomarkers measured
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TABLE 1 | Perinatal condition of the study population.
CVT (any type)
n = 36
CVT (only Cat)
n = 17
No CVT
n = 62
p-value
CVT (any type) vs. no CVT CVT (only Cat) vs. no CVT
GA, weeks (mean, SD) 26.4 (1.7) 27.0 (1.4) 28.5 (1.8) 0.000 0.002
BW, g (mean, SD) 876 (284) 835 (284) 1,105 (312) 0.000 0.002
Maternal age, years (mean, SD) 32.6 (5.6) 32.6 (5.2) 32.7 (6.4) 0.821 0.971
Apgar 5min < 5, n (%) 4 (11.1) 4 (23.5) 2 (3.5) 0.188 0.018
SNAPPE-II > 45, n (%) 16 (45.7) 11 (68.8) 5 (8.2) 0.000 0.000
Cord pH, n (%) 7.22 (0.2) 7.17 (0.2) 7.29 (0.1) 0.368 0.025
PROM > 24 h, n (%) 9 (25) 2 (11.8) 13 (21) 0.802 0.503
Advanced resuscitation, n (%)* 22 (61.1) 12 (70.6) 11 (17.7) 0.000 0.000
Chorioamnionitis, n (%)
†
9 (25) 3 (17.6) 12 (19.4) 0.611 1
Antenatal steroids, n (%)z 25 (69.4) 11 (64.7) 56 (90.3) 0.012 0.018
Maternal hypertension, n (%) 5 (13.9) 4 (23.5) 10 (16.1) 1 0.486
SGA, n (%) 7 (19.4) 6 (35.3) 12 (19.4) 1 0.197
Multiple, n (%) 5 (13.9) 3 (17.6) 20 (32.3) 0.056 0.367
Male, n (%) 26 (72.2) 12 (70.6) 29 (46.8) 0.020 0.104
C-section, n (%) 24 (66.7) 15 (88.2) 44 (71) 0.657 0.212
Cardiovascular treatment (CVT), volume expansion and/or catecholamine (dopamine, epinephrine) plus/minus hydrocortisone; Cat, catecholamine; SGA, small for gestational age;
SNAPPE-II, Score for Neonatal Acute Physiology Perinatal Extension-II (38), PROM, premature rupture of membranes.
* Intubation in the delivery room with or without assisted circulation.
†
Histological chorioamnionitis.
Z Completed course.
at baseline showed trends toward an increased risk of adverse
outcome, but with no association with adverse outcome since
all 95% CI span the null value (OR = 1) and p values were
not statistically significant: Base excess < −9, serum lactate > 4
mmol/L, and SVC flow < 51 ml/kg/min. Results were the same
after adjusting by gestational age.
DISCUSSION
This retrospective pilot study has found that low blood pressure
and high serum lactate levels were the biomarkers more
frequently present at the start of CVT. Of note, BE worse
than −9, serum lactate > 4 mmol/L, and SVC flow < 51
ml/kg/min, showed a trend toward increased likelihood of
combined adverse outcome in this series, although this did not
reach statistical significance.
The use of a variety of clinical signs, mainly management
of blood pressure, to initiate CVT in the hope of maintaining
adequate organ blood flow, has possibly led to overdiagnosis and
overtreatment in the preterm infants. This is extremely important
as the prescribed medicines could cause more harm than benefit
(6–8, 20). Or it may be the case that, the disease causing the
circulatory disturbance, the resultant abnormalities in blood flow
distribution, or both, irrespective of treatment, could be the main
determinants of the increased risk for adverse outcome in these
infants (21).
There is no doubt that studies to define which infants would
benefit from treatment or not are of utmost relevance (5).
Hypotension, whatever the definition used, is the most frequent
clinical parameter used to initiate treatment (3, 4, 11, 22); as also
shown in the present study. However, a recent study revealed
that irrespective of early changes in blood pressure, extremely
preterm infants who received antihypotensive therapy in the first
24 h after birth had a significantly higher rate of death or impaired
neurodevelopment at 2 years than those who were not treated,
after controlling for illness severity (8).
The second important reflection is about the CVT to be
chosen in a given condition. The distribution of cardiac output
is dependent on the interplay among the various components
of the cardiovascular system, both cardiac and extracardiac
factors. The cardiovascular drugs, particularly catecholamines,
act at different parts of this complex system, exerting different
pharmacodynamic effects (10, 11). So far, even if we are
able to identify who would benefit from treatment, if the
pharmacodynamic effect of the chosen drug does not fit the
pathophysiology of the condition, it could be counterproductive,
impairing blood flow distribution or oxygen transport.
Thus, our proposal to use a combination of biomarkers
addresses the possible failure of both the macro- and
microcirculation. Such an approach has been used in previous
observational studies (6). The macrocirculation is evaluated
at the vascular (blood pressure) and at the heart level (SVC
flow as an estimate of cardiac output). The adequacy of the
microcirculation is proposed to be assessed by the use of lactate
and BE as surrogates of tissue oxygen delivery and extraction
(22, 23). It is true that sites differ in facilities and protocols to
implement this in a standardized way, but considering using
a combination of these biomarkers would probably help them
better define both the clinical picture and the condition to
address. We support the use of these “objective” biomarkers
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TABLE 2 | Main neonatal clinical outcomes at term equivalence.
CVT (any type)
n = 36
CVT (only Cat)
n = 17
No CVT
n = 62
p-value
CVT (any type) vs. no CVT CVT (only Cat) vs. no CVT
Mortality, n (%) 7 (19.4) 2 (11.8) 2 (3.2) 0.3 0.4
Combined adverse outcome, n (%) 26 (72.2) 13 (76.4) 21 (33.9) 0.002 0.001
Normal cUS, n (%) 10 (27.8) 4 (23.5) 42 (67.7) 0.02 0.01
IVH grade 3 or 4, n (%) 10 (27.8) 6 (35.3) 1 (1.6) 0.01 0.005
White matter damage, n (%) 12 (33.3) 7 (41.2) 7 (11.3) 0.09 0.04
NEC, n (%) 5 (13.9) 1 (5.9) 8 (12.9) 0.8 0.4
Age at full enteral feeds in days (mean, SD) 24.5 (13) 26.5 (14) 16 (14) 0.2 0.1
PDA treated, n (%) 24 (66.7) 14 (82.4) 17 (27.4) 0.3 0.2
Mechanical ventilation in days (mean, SD) 44 (38) 52 (36) 8.9 (13) 0.000 0.000
O2 dependency at 36 weeks, n (%) 18 (50) 11 (64.7) 5 (8.1) 0.001 0.000
Laser therapy for ROP, n (%) 9 (25) 4 (23.5) 3 (4.8) 0.1 0.09
Age at discharge in days (mean, SD) 109.6 (48) 118 (55) 61.6 (24) 0.000 0.000
Logistic regression analysis adjusted by gestational age.
Cardiovascular treatment (CVT), volume expansion and/or catecholamine (dopamine, epinephrine); Cat, catecholamine; combined adverse outcome was defined as death or moderate-
severe brain damage according to the ultrasound exam performed at term equivalent [intraventricular hemorrhage grade 3; or periventricular hemorrhagic infarct; or white matter damage
(persistent periventricular echogenicity with/without ventriculomegaly or cystic periventricular leukomalacia)]; IVH, intraventricular hemorrhage; ROP, retinopathy of prematurity.
FIGURE 1 | Retrospective assessment (R) of biomarkers influencing treatment
decisions.
instead of other routine clinical parameters such as tachycardia,
urine output, capillary refill time, or core-to-peripheral
temperature gap; which seem to have a higher variability, are
more influenced by external factors and have non-existent or too
wide normative values for the target population (24–28).
Although negative BE has been an insensitive indicator of
raised lactate concentrations in other papers (22), we observed
that infants with combined adverse outcome presented more
frequently a trend toward a negative BE worse than −9 mmol/L
although not statistically significant. Cotside measurement of
serum lactate is currently feasible in most NICUs, so this
biomarker can be proposed as a routine biochemical tool.
As previously reported (8, 19) we have found an increased
risk of death if any CVT is used, the odds being higher if
catecholamines are added to the treatment. However, this just
shows an association and not a cause-and-effect. So far, no
randomized clinical trial to reach definitive conclusions has
been published.
TABLE 3 | Biomarker status at start of cardiovascular treatment.
Biomarker
n (%)
CVT
(any type)
n = 36
CVT
(only Cat)
n = 17
No CVT
n = 62
p-value
CVT
(any type)
vs.
no CVT
CVT
(only Cat)
vs.
no CVT
MABP < GA-1 mmHg 10 (27.7) 8 (47) 7 (11.3) 0.049 0.002
MABP < GA-5 mmHg 2 (5.5) 2 (11.8) 1 (1.6) 0.55 0.11
Lactate > 4 mmol/L 11 (30.6) 8 (47) 2 (3.2) 0.000 0.000
BE < −9 mmol/L 4 (11.1) 4 (23.5) 3 (4.8) 0.42 0.03
Cardiovascular treatment (CVT), volume expansion and/or catecholamine (dopamine,
epinephrine plus/minus hydrocortisone); Cat, catecholamine.
This work has explored the role of the proposed cut-off values
as prognostic biomarkers. One limitation is that, because CVT
in the normal flow group did not follow a specific protocol, it is
difficult to elucidate if adverse outcome is caused by processes
related to the biomarkers or as an effect of treatment. Data from
a randomized controlled trial with dobutamine will help confirm
their predictive value for treatment with this drug, or if they
can be validated in other capacity for clinical trial purposes, e.g.,
safety, monitoring, pharmacodynamic/response, or other type of
biomarker. Note that it may very well be the case that these
biomarkers are prognostic (i.e., they indicate poor prognosis) but
not predictive (i.e., they do not identify patients that may benefit
from treatment). Another limitation of this study is the fact that a
more in depth analysis to explore whether potential confounders
(SNAPPE scores, advanced resuscitation, cord pH, antenatal
steroids. . . ) could have had an impact on the observed association
between CVT and adverse outcome, was not done. However,
CVT (any type) and CVT (only catecholamines) showed a
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TABLE 4 | Association between early positive biomarker and combined adverse outcome in the study population.
Biomarkers at birth (first 2h of life) Biomarkers at baseline* (time of first Echo-D)
Biomarkers (BM) Adverse outcome§ OR
(95%CI)
p-value Adverse outcome§ OR
(95%CI)
p-value
Yes No Yes No
SVC flow < 51 (n = 0 at birth,
n = 98 at baseline)
BM+ – – – – 5/8
(62.5)
3/8
(37.5)
4.1
(0.9–18.4)
0.10
BM– – – 26/90
(28.9)
64/90
(71.1)
MABP < GA-1 (n = 89 at
birth, n = 93 at baseline)
BM+ 6/26
(23.1)
20/26
(76.9)
0.6
(0.21–1.7)
0.45 7/17
(41.2)
10/17
(58.8)
1.9
(0.6–5.8)
0.2
BM– 21/63
(33.3)
42/63
(66.7)
20/76
(26.3)
56/76
(73.7)
MABP < GA-5 (n = 89 at
birth, n = 93 at baseline)
BM+ 2/8
(25)
6/8
(75)
0.7
(0.14–3.9)
1.00 2/2
(100)
(0)
0/2
Z 0.08
BM– 25/81
(30.9)
56/81
(69.1)
25/91
(27.5)
66/91
(72.5)
Lactate > 4 mmol/L (n = 90
at birth, n = 93 at baseline)
BM+ 11/25
(44)
14/25
(56)
2.2
(0.85–5.8)
0.13 9/18
(50)
9/18
(50)
2.6
(0.9–7.4)
0.09
BM– 17/65
(26.2)
48/65
(73.8)
21/75
(28)
54/75
(72)
BE < −9 mmol/L (n = 88 at
birth, n = 97 at baseline)
BM+ 5/11
(45.5)
6/11
(54.5)
2.08
(0.58–7.5)
0.30 5/9
(55.6)
4/9
(44.4)
3.15
(0.8–12.7)
0.13
BM– 22/77
(28.6)
55/77
(71.4)
25/88
(28.4)
63/88
(71.6)
§Adverse Outcome is defined as death or intraventricular hemorrhage grade 3 or periventricular hemorrhagic infarction or white matter damage.
*Baseline, time at first Echo-D [5 (3) h from birth]. Study biomarkers are not always documented in all the study time points.
ZOR could not be calculated as all the infants with MABP < GA-5 presented adverse outcome.
positive association with the risk of death or moderate-severe
abnormal cranial ultrasound at term equivalent adjusted for
gestational age. Thus, it was considered that the most powerful
confounding factor was taken in consideration and this is of great
interest in itself.
For this work we used the BEST (Biomarkers, EndpointS, and
other Tools) resource from the FDA-NIH Biomarker Working
Group, aiming to be as consistent as possible in the use of
definitions and key terms around biomarkers. We believe this
is needed for true effective communication, evaluation and
interpretation of scientific evidence in this field of research (39).
CONCLUSIONS
This retrospective pilot analysis has found that high serum lactate
levels and low blood pressure are the most prevalent biomarkers
used to prescribe CVT in this cohort of preterm infants. In
addition to low SVC flow, high lactate serum levels and worse BE
showed a trend toward being associated with adverse outcome.
The findings support the use of these prognostic biomarkers
as entry criterion in randomized placebo-controlled trials on
cardiovascular support for circulatory impairment during the
transitional circulation in the preterm infant.
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